Amlodipine 10mg Tablets
Out of date information, search anotherSUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Amlodipine 10 mg Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 10 mg Amlodipine as Amlodipine Besilate.
For full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Tablet
White to off white, round, biconvex, uncoated tablets with ‘10’ embossing on one side.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Hypertension
Prophylaxis of chronic stable angina pectoris and Prinzmental’s (Variant) angina when diagnosed by a cardiologist.
4.2 Posology and method of administration Posology
In adults
For both hypertension and angina the usual initial dose is 5 mg Amlodipine tablets once daily which may be increased to a maximum dose of 10 mg depending on the individual patient’s response.
In hypertensive patients, Amlodipine has been used in combination with a thiazide diuretic, alpha-blocker, beta-adrenergic blocking agent, or an angiotensin converting enzyme inhibitor. For angina, Amlodipine may be used as monotherapy or in combination with other antianginal drugs in patients with angina that is refractory to nitrates and /or adequate doses of beta blockers.
No dose adjustment of Amlodipine Tablets is required upon concomitant administration of thiazide diuretics, beta blockers, and angiotensin- converting enzyme inhibitors.
Special populations
Use in children
Children and adolescents with hypertension from 6 years to 17 years of age.:
The recommended antihypertensive oral dose in paediatric patients ages 6-17 years is 2.5 mg once daily as a starting dose, up-titrated to 5 mg once daily if blood pressure goal is not achieved after 4 weeks. Doses in excess of 5 mg daily have not been studied in pediatric patients (see section 5.1 and 5.2).
Children under 6 years old
The effect of amlodipine on blood pressure in patients less than 6years of age is not known.
Use in the elderly
Amlodipine tablets, used at similar doses in elderly or younger patients, is equally well tolerated. Therefore normal dosage regimens are recommended in the elderly, but increase of the dosage should take place with care (see sections 4.4 and 5.2)
Patients with hepatic impairment
Dosage recommendations have not been established in patients with mild to moderate hepatic impairment; therefore dose selection should be cautious and should start at the lower end of the dosing range (see sections 4.4 and 5.2).
The pharmacokinetics of amlodipine have not been studied in severe hepatic impairment. Amlodipine should be initiated at the lowest dose and titrated slowly in patients with severe hepatic impairment.
Patients with renal impairment
Changes in Amlodipine plasma concentrations are not correlated with degree of renal impairment, therefore the normal dosage is recommended.
Amlodipine is not dialysable.
Method of administration
Tablet for oral administration
4.3 Contraindications
Amlodipine Tablets are contraindicated in
. Patients with known sensitivity to Dihydropyridine derivatives,
Amlodipine or any of the excipients.
. • Severe hypotension
. • Shock -(including cardiogenic shock)
. Obstruction of the outflow tract of the left ventricle (e.g high grade
aortic stenosis)
. Haemodynamically unstable heart failure after acute myocardial
infarction.
4.4 Special warnings and precautions for use
The safety and efficacy of amlodipine in hypertensive crisis has not been established.
Patients with cardiac failure
Patients with heart failure shoud be treated with caution. In a long-term, placebo controlled study (PRAISE-2) of Amlodipine in patients with NYHA III and IV heart failure of nonischaemic aetiology, amlodipine was associated with increased reports of pulmonary oedema despite no significant difference in the incidence of worsening heart failure as compared to placebo (see section
5.1 ). Calcium channel blockers, including amlodipine, should be used with caution in patients with congestive heart failure, as they may increase the risk of future cardiovascular events and mortality.
Use in patients with impaired hepatic function
As with all calcium antagonists, Amlodipine’s half-life is prolonged and AUC values are higher in patients with impaired liver function and dosage recommendations have not been established. Amlodipine should therefore be initiated at the lower end of the dosing range. The drug should therefore be administered with caution and slow dose titration may be required in these patients.
Use in elderly patients
In the elderly increase of the dosage should take place with care (see sections
4.2 and 5.2).
Use in renal failure
Amlodipine may be used in such patients at normal doses. Changes in amlodipine plasma concentrations are not correlated with degree of renal impairment. Amlodipine is not dialysable
4.5 Interaction with other medicinal products and other forms of interaction Effect of other medicinal products on amlodipine
CYP3A4 inhibitors: Concomitant use of amlodipine with strong or moderate CYP3A4 inhibitors (protease inhibitors, azole antifungals, macrolides like erythromycin or clarithromycin, verapamil or diltiazem) may give rise to significant increase in amlodipine exposure. The clinical translation of these PK variations may be more pronounced in the elderly. Clinical monitoring and dose adjustment may thus be required.
CYP3A4 inducers: There is no data available regarding the effect of CYP3A4 inducers on amlodipine. The concomitant use of CYP3A4 inducers (e.g., rifampicin, hypericum perforatum) may give a lower plasma concentration of amlodipine. Amlodipine should be used with caution together with CYP3A4 inducers. Administration of amlodipine with grapefruit or grapefruit juice is not recommended as bioavailability may be increased in some patients resulting in increased blood pressure lowering effects.
Dantrolene (infusion): In animals, lethal ventricular fibrillation and cardiovascular collapse are observed in association with hyperkalemia after administration of verapamil and intravenous dantrolene. Due to risk of hyperkalemia, it is recommended that the co-administration of calcium channel blockers such as amlodipine be avoided in patients susceptible to malignant hyperthermia and in the management of malignant hyperthermia.
Effect of amlodipine on other medicinal products
The blood pressure lowering effects of amlodipine adds to the blood pressurelowering effects of other medicinal products with antihypertensive properties.
Digoxin: Co-administration of amlodipine with digoxin did not change serum digoxin levels or digoxin renal clearance in normal volunteers.
Warfarin: In healthy male volunteers, the co-administration of amlodipine does not significantly alter the effect of warfarin on prothrombin response time. Co-administration of amlodipine with warfarin did not change the warfarin prothrombin response time.
Ciclosporin: Pharmacokinetic studies with ciclosporin have demonstrated that amlodipine does not significantly alter the pharmacokinetics of ciclosporin.
Simvastatin: Co-administration of multiple doses of 10 mg of amlodipine with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone. Limit the dose of simvastatin to 20 mg daily in patients on amlodipine
4.6 Fertility, pregnancy and lactation
Pregnancy The safety of amlodipine in human pregnancy has not been established.
In animal studies, reproductive toxicity was observed at high doses (see section 5.3).
Use in pregnancy is only recommended when there is no safer alternative and when the disease itself carries greater risk for the mother and foetus.
Breast-feeding It is not known whether amlodipine is excreted in breast milk. A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with amlodipine should be made taking into account the benefit of breastfeeding to the child and the benefit of amlodipine therapy to the mother.
Fertility Reversible biochemical changes in the head of spermatozoa have been reported in some patients treated by calcium channel blockers. Clinical data are insufficient regarding the potential effect of amlodipine on fertility. In one rat study, adverse effects were found on male fertility (see section 5.3).
4.7 Effects on ability to drive and use machines
Amlodipine can have minor or moderate influence on the ability to drive and use machines. If patients taking amlodipine suffer from dizziness, headache, fatigue or nausea the ability to react may be impaired. Caution is recommended especially at the start of treatment.
4.8 Undesirable effects
Summary of the safety profile
The most commonly reported adverse reactions during treatment are somnolence, dizziness, headache, palpitations, flushing, abdominal pain, nausea, ankle swelling, oedema and fatigue.
Adverse events that have been reported in amlodipine trials are categorised below, according to system organ class and frequency. Frequencies are defined as: very common (>10%); common (>1%, <10%); uncommon (>0.1%, <1%); rare (>0.01%, <0.1%) and very rare (<0.01%).
|
System organ class |
Adverse reactions |
Frequency |
|
Blood and the lymphatic system disorders |
Thrombocytopenia, leukocytopenia |
Very rare |
|
Immune system disorders |
Allergic reaction |
Very rare |
|
Metabolism and nutrition disorders |
Hyperglycaemia |
Very rare |
|
Psychiatric disorders |
Insomnia, mood changes (including anxiety), depression |
Uncommon |
|
Confusion |
Rare | |
|
Nervous system disorders |
Somnolence, dizziness, headache (especially at the beginning of the treatment) |
Common |
|
Tremor, taste perversion, syncope, hypoaesthesia, paraesthesia |
Uncommon | |
|
Hypertonia, peripheral neuropathy |
Very rare | |
|
Eye disorders |
Visual disturbances (including diplopia) |
Uncommon |
|
Ear and labyrinth disorders |
Tinnitus |
Uncommon |
|
Cardiac disorders |
Palpitations |
Common |
|
Myocardial infarction, arrhythmia, ( including bradycardia,ventricular |
Very rare |
|
tachycardia and atrial fibrillation) | ||
|
Vascular disorders |
Flushing |
Common |
|
Hypotension |
Uncommon | |
|
Vasculitis |
Very rare | |
|
Respiratory, thoracic and Mediastinal disorders |
Dyspnoea, rhinitis |
Uncommon |
|
Cough |
Very rare | |
|
Gastrointestinal disorders |
Abdominal pain, nausea |
Common |
|
Vomiting, dyspepsia, altered bowel habits (including diarrhoea and constipation), dry mouth |
Uncommon | |
|
Pancreatitis, gastritis, gingival hyperplasia |
Very rare | |
|
Hepato-biliary disorders |
Hepatitis, jaundice and hepatic enzyme elevations (mostly consistent with cholestasis) |
Very rare |
|
Skin and subcutaneous tissue disorders |
Alopecia, purpura, skin discolouration, increased |
Uncommon |
|
sweating, pruritus, rash, exanthema | ||
|
Angioedema, erythema multiforme, urticaria, exfoliative dermatitis, Stevens-Johnson syndrome, Quincke oedema, photosensitivity |
Very rare | |
|
Musculoskeletal and connective tissue disorders |
Arthralgia, myalgia, muscle cramps, back pain |
Uncommon |
|
Ankle swelling |
Common | |
|
Renal and urinary disorders |
Micturition disorder, nocturia, increased urinary frequency |
Uncommon |
|
Reproductive system and breast disorders |
Impotence, gynaecomastia |
Uncommon |
|
General disorders and administration site conditions |
Oedema, fatigue |
Common |
|
Chest pain, asthenia, pain, malaise |
Uncommon | |
|
Investigations |
Weight increase, weight decrease |
Uncommon |
Exceptional cases of extrapyramidal syndrome have been reported.
Reporting of Suspected Adverse Reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
4.9 Overdose
In humans experience with intentional overdose is limited.
Symptoms
Available data suggest that gross overdosage could result in excessive peripheral vasodilatation and possibly reflex tachycardia. Marked and probably prolonged systemic hypotension up to and including shock with fatal outcome have been reported.
Treatment
Administration of activated charcoal to healthy volunteers immediately or up to two hours after ingestion of amlodipine 10mg has been shown to significantly decrease amlodipine absorption. Gastric lavage may be worthwhile in some cases.
Clinically significant hypotension due to amlodipine overdosage calls for active cardiovascular support including frequent monitoring of cardiac and respiratory function, elevation of extremities, and attention to circulating fluid volume and urine output.
A vasoconstrictor may be helpful in restoring vascular tone and blood pressure, provided that there is no contraindication to its use. Intravenous calcium gluconate may be beneficial in reversing the effects of calcium channel blockade. Since amlodipine is highly protein-bound, dialysis is not likely to be of benefit.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Calcium channel blockers, selective calcium channel blockers with mainly vascular effects ATC Code: C08CA01
Amlodipine is a calcium ion influx inhibitor of the dihydropyridine group (slow channel blocker or calcium ion antagonist) and inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle.
The mechanism of the antihypertensive action of amlodipine is due to a direct relaxant effect on vascular smooth muscle. The precise mechanism by which Amlodipine relieves angina has not been fully determined but Amlodipine reduces total ischaemic burden by the following two actions.
1) Amlodipine dilates peripheral arterioles and thus, reduces the total peripheral resistance (afterload) against which the heart works. Since the heart
rate remains stable, this unloading of the heart reduces myocardial energy consumption and oxygen requirements.
2) The mechanism of action of amlodipine also probably involves dilatation of the main coronary arteries and coronary arterioles, both in normal and ischaemic regions. This dilatation increases myocardial oxygen delivery in patients with coronary artery spasm (Prinzmetal's or variant angina).
In patients with hypertension, once daily dosing provides clinically significant reductions of blood pressure in both the supine and standing positions throughout the 24 hour interval. Due to the slow onset of action, acute hypotension is not a feature of amlodipine administration.
In patients with angina, once daily administration of amlodipine increases total exercise time, time to angina onset, and time to 1mm ST segment depression, and decreases both angina attack frequency and glyceryl trinitrate tablet consumption.
Amlodipine has not been associated with any adverse metabolic effects or changes in plasma lipids and is suitable for use in patients with asthma, diabetes, and gout.
Use in patients with coronary artery disease (CAD)
The effectiveness of amlodipine in preventing clinical events in patients with coronary artery disease (CAD) has been evaluated in an independent, multicentre, randomized, double- blind, placebo-controlled study of 1997 patients; Comparison of Amlodipine vs. Enalapril to Limit Occurrences of Thrombosis (CAMELOT). Of these patients, 663 were treated with amlodipine 5-10 mg, 673 patients were treated with enalapril 10-20 mg, and 655 patients were treated with placebo, in addition to standard care of statins, beta-blockers, diuretics and aspirin, for 2 years. The key efficacy results are presented in Table 1. The results indicate that amlodipine treatment was associated with fewer hospitalizations for angina and revascularization procedures in patients with CAD.
|
Table 1. Incidence of significant clinical outcomes for CAMELOT | |||||
|
Cardiovascular event rates, No. (%) |
Amlopidine vs. Placebo | ||||
|
Outcomes |
Amlopidine |
Placebo |
Enalapril |
Hazard Ratio (95% CI) |
P Value |
|
Primary Endpoint | |||||
|
Adverse cardiovascular events |
110 (16.6) |
151 (23.1) |
136 (20.2) |
0.69 (0.540.88) |
.003 |
|
Individual Components | |||||
|
Coronary revascularization |
78 (11.8) |
103 (15.7) |
95 (14.1) |
0.73 (0.540.98) |
.03 |
|
Hospitalization for angina |
51 (7.7) |
84 (12.8) |
86 (12.8) |
0.58 (0.410.82) |
.002 |
|
Nonfatal MI |
14 (2.1) |
19 (2.9) |
11 (16) |
0.73 (0.371.46) |
.37 |
|
Stroke or TIA |
6 (0.9) |
12 (1.8) |
8 (1.2) |
0.50 (0.191.32) |
.15 |
|
Cardiovascular death |
5 (0.8) |
2 (0.3) |
5 (0.7) |
2.46 (0.4812.7) |
.27 |
|
Hospitalization for CHF |
3 (0.5) |
5 (0.8) |
4 (0.6) |
0.59 (0.142.47) |
.46 |
|
Resuscitated cardiac arrest |
0 |
4 (0.6) |
1 (0.1) |
NA |
.04 |
|
New-onset peripheral vascular disease |
5 (0.8) |
2 (0.3) |
8 (1.2) |
2.6 (0.5013.4) |
.24 |
Abbreviations: CHF, congestive heart failure; CI, confidence interval; MI, myocardial infarction; TIA, transient ischemic attack.
Use in patients with heart failure
Haemodynamic studies and exercise based controlled clinical trials in NYHA Class II-IV heart failure patients have shown that amlodipine did not lead to clinical deterioration as measured by exercise tolerance, left ventricular ejection fraction and clinical symptomatology.
A placebo controlled study (PRAISE) designed to evaluate patients in NYHA Class III-IV heart failure receiving digoxin, diuretics and ACE inhibitors has shown that amlodipine did not lead to an increase in risk of mortality or combined mortality and morbidity with heart failure.
In a follow-up, long term, placebo controlled study (PRAISE-2) of amlodipine in patients with NYHA III and IV heart failure without clinical symptoms or objective findings suggestive or underlying ischaemic disease, on stable doses of ACE inhibitors, digitalis, and diuretics, amlodipine had no effect on total cardiovascular mortality. In this same population Amlodipine was associated with increased reports of pulmonary oedema despite no significant difference in the incidence of worsening heart failure as compared to placebo.
Treatment to prevent heart attack trial (ALLHAT)
A randomized double-blind morbidity-mortality study called the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) was performed to compare newer drug therapies: amlodipine 2.510 mg/d (calcium channel blocker) or lisinopril 10-40 mg/d (ACE-inhibitor) as first-line therapies to that of the thiazide-diuretic, chlorthalidone 12.5-25 mg/d in mild to moderate hypertension.”
A total of 33,357 hypertensive patients aged 55 or older were randomized and followed for a mean of 4.9 years. The patients had at least one additional CHD risk factor, including: previous myocardial infarction or stroke > 6 months prior to enrolment) or documentation of other atherosclerotic CVD (overall 51.5%), type 2 diabetes (36.1%), HDL-C < 35 mg/dL (11.6%), left ventricular hypertrophy diagnosed by electrocardiogram or echocardiography (20.9%), current cigarette smoking (21.9%).
The primary endpoint was a composite of fatal CHD or non-fatal myocardial infarction. There was no significant difference in the primary endpoint between amlodipine-based therapy and chlorthalidone-based therapy: RR 0.98 95% CI(0.90-1.07) p=0.65.Among Secondary Endpoints, the incidence of heart failure (component of a composite combined cardiovascular endpoint) was significantly higher in the amlodipine group as compared to the chlorthalidone group (10.2% % vs 7.7%, RR 1.38, 95% CI [1.25-1.52] p<0.001). However, there was no significant difference in all-cause mortality between amlodipine-based therapy and chlorthalidone-based therapy. RR 0.96 95% CI [0.89-1.02] p=0.20.
In a study involving 268 children aged 6-17 years with predominantly secondary hypertension, comparison of a 2.5mg dose, and 5.0mg dose of amlodipine with placebo, showed that both doses reduced Systolic Blood Pressure significantly more than placebo. The difference between the two doses was not statistically significant.
The long-term effects of amlodipine on growth, puberty and general development have not been studied. The long-term efficacy of amlodipine on therapy in childhood to reduce cardiovascular morbidity and mortality in adulthood have also not been established.
5.2 Pharmacokinetic properties
Absorption , distribution, plasma protein binding
After oral adminstration of therapeutic doses, Amlodipine is well absorbed with peak blood levels between 6-12 hours post dose. Absolute bioavailability has been estimated to be between 64 and 80%. The volume of distribution is approximately 21 l/Kg. In vitro studies have shown that approximately 97.5% of circulating Amlodipine is bound to plasma proteins.
The bioavailability of amlodipine is not affected by food intake.
Biotransformation/ elimination
The terminal plasma elimination half-life is about 35-50 hours and is consistent with once daily dosing. Amlodipine is extensively metabolised by the liver to inactive metabolites with 10% of the parent compound and 60% of metabolites excreted in the urine.
Use in hepatic impairment
Very limited clinical data are available regarding amlodipine administration in patients with hepatic impairment. Patients with hepatic insufficiency have decreased clearance of amlodipine resulting in a longer half-life and an increase in AUC of approximately 40-60%.
Use in the elderly
The time to reach peak plasma concentrations of Amlodipine is similar in elderly and younger subjects. Amlodipine clearance tends to be decreased with resulting increase in AUC and elimination half-life in elderly patients. Increases in AUC and elimination half-life in patients with congestive heart failure were as expected for the patient age group studies.
Use in children
A population PK study has been conducted in 74 hypertensive children aged from 12 month to 17 years (with 34 patients aged 6 to 12 years and 28 patients aged 13 to 17 years) receiving amlodipine between 1.25 and 20 mg given either once or twice daily. In children 6 to 12 years and in adolescents 13-17 years of age the typical oral clearance (CL/F) was 22.5 and 27.4 L/hr respectively in males and 16.4 and 21.3 L/hr respectively in females . Large variability in exposure between individuals was observed. Data reported in children below 6 years is limited.
5.3 Preclinical safety data Reproductive toxicology
Reproductive studies in rats and mice have shown delayed date of delivery, prolonged duration of labour and decreased pup survival at dosages approximately 50 times greater than the maximum recommended dosage for humans based on mg/kg.
Impairment of fertility
There was no effect on the fertility of rats treated with amlodipine (males for 64 days and females 14 days prior to mating) at doses up to 10 mg/kg/day (8 times1 the maximum recommended human dose of 10 mg on a mg/m2 basis). In another rat study in which male rats were treated with amlodipine besilate for 30 days at a dose comparable with the human dose based on mg/kg, decreased plasma follicle-stimulating hormone and testosterone were found as well as decreases in sperm density and in the number of mature spermatids and Sertoli cells.
Carcinogenesis, mutagenesis
Rats and mice treated with amlodipine in the diet for two years, at concentrations calculated to provide daily dosage levels of 0.5, 1.25, and 2.5 mg/kg/day showed no evidence of carcinogenicity. The highest dose (for mice, similar to, and for rats twice1 the maximum recommended clinical dose of 10 mg on a mg/m2 basis) was close to the maximum tolerated dose for mice but not for rats.
Mutagenicity studies revealed no drug related effects at either the gene or chromosome levels.
PHARMACEUTICAL PARTICULARS
6
6.1 List of excipients
Calcium hydrogen phosphate dihydrate Microcrystalline cellulose Silica colloidal anhydrous Sodium starch glycollate Magnesium stearate
6.2 Incompatibilities
None Known
6.3 Shelf life
3 years.
6.4 Special precautions for storage Blisters: Do not store above 25°C.
Store in the original package.
Bulk: Do not store above 25°C.
Keep the container tightly closed.
6.5 Nature and contents of container
Aluminium/PVDC coated PVC blister strips containing 14 tablets. Blister strips packaged into outer container to give total of 28, 56, 84 tablets.
The tablets are also packed in HDPE containers containing 100, 250, 500 tablets.
Not all pack sizes may be marketed.
6.6 Special precautions for disposal
No special requirements.
7 MARKETING AUTHORISATION HOLDER
Bristol Laboratories Limited Unit 3, Canalside, Northbridge Road,
Berkhamsted, Herts,
HP4 1EG United Kingdom
8 MARKETING AUTHORISATION NUMBER(S)
PL 17907/0086
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
09/03/2007
10 DATE OF REVISION OF THE TEXT
27/08/2014
Based on patient weight of 50 kg